Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Neural Regulation01:37

Neural Regulation

43.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.6K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

748
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
748
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stage-dependent tau-PET signatures in Huntington's disease revealed by [¹⁸F]PI-2620.

European journal of nuclear medicine and molecular imaging·2026
Same author

Practice effects as a dynamic biomarker of early cognitive change in far-from-onset Huntington's disease.

Brain communications·2026
Same author

Minimal clinically important difference for cognitive scales in people with Parkinson's disease with cognitive impairment.

Scientific reports·2026
Same author

Parkinson's disease-subjective cognitive decline and health-related quality of life.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Unraveling the genetic architecture of non-Huntington chorea: a biobank-scale study of rare variants and repeat expansions.

NPJ genomic medicine·2026
Same author

Spontaneous speech and language measures as predictive biomarkers of clinically meaningful disease progression and neurodegeneration in Huntington's disease.

Journal of neural transmission (Vienna, Austria : 1996)·2026

Related Experiment Video

Updated: Feb 24, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.5K

Apathy in Parkinson's Disease.

Javier Pagonabarraga1, Jaime Kulisevsky1

  • 1Movement Disorders Unit, Sant Pau Hospital and Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain; Universitat Oberta de Catalunya (U.O.C.), Barcelona, Spain.

International Review of Neurobiology
|August 14, 2017
PubMed
Summary

Apathy in Parkinson's disease significantly impacts quality of life. Differentiating apathy subtypes and understanding associated brain systems can guide personalized treatments for this motivation deficit.

Keywords:
ApathyCognitive impairmentDepressionDopamine agonistsMethylphenidateParkinson's disease

More Related Videos

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

19.0K
Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.4K

Related Experiment Videos

Last Updated: Feb 24, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.5K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

19.0K
Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.4K

Area of Science:

  • Neuroscience
  • Neurology
  • Psychiatry

Background:

  • Apathy is common in Parkinson's disease, affecting patient and caregiver quality of life.
  • Apathy symptoms can be mistaken for depression or executive dysfunction.
  • Current treatment approaches for apathy are lacking.

Purpose of the Study:

  • To review distinct apathetic syndromes and their diagnostic scales.
  • To identify the brain systems underlying different apathy subtypes.
  • To inform individualized treatment strategies for apathy.

Main Methods:

  • Literature review of apathetic syndromes and associated neurobiology.
  • Analysis of diagnostic scales for clinical differentiation of apathy.
  • Correlation of brain systems with potential therapeutic targets.

Main Results:

  • Apathy presents as distinct clinical syndromes.
  • Specific subcortical and prefrontal-limbic pathways are implicated in apathy.
  • Understanding these systems may explain treatment responses.

Conclusions:

  • Clinical differentiation of apathy is crucial for effective management.
  • Targeting specific brain systems offers potential for individualized apathy treatment.
  • Further research into neurobiological underpinnings can guide therapeutic interventions.